When Good Things DON’T Come to Those Who Wait: How Pharma Companies Compare in Governance Efficiency


Predicting when a competing product will be approved is essential in any commercial forecast and for any business insights team with their eye on the market.  Here at OZMOSI, we have been spending our summer building out a machine learning approach to further improve our drug approval date forecasting.  Typically, the industry uses a simple average of phase lengths by disease area. While we have employed a similar approach historically, with 400,000 clinical trials in our database (and counting) we feel we can do better. In our analysis to date, we have gained some interesting perspective on the elements that go [...]